Clinical outcome of concurrent chemo-radiotherapy for patients with stage Ⅳ non-small cell lung cancer
10.3760/cma.j.issn.1004-4221.2009.01.052
- VernacularTitle:Ⅳ期非小细胞肺癌同期化放疗的临床结果分析
- Author:
Heyi FU
;
Bing LU
;
Huaning ZHOU
;
Weiwei OUYANG
;
Shengfa SU
;
Yinxiang HU
;
Jiaying GAN
;
Weili WU
;
Haiqin LI
- Publication Type:Journal Article
- Keywords:
Lung neoplasms/ehemo-radiotherapy;
Lung neoplasms/radiotherapy;
Lung neo plasms/chemotherapy;
Concurrent ehemo-radiotherapy;
Sequentially ehemo-radiotherapy;
Three-dimensional conformal;
Late-course accelerated;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2009;18(1):52-56
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical outcome of concurrent ehemo-radiotherapy in stage Ⅳ non-small cell lung cancer(NSCLC).Methods From Jan.1997 to Dec.2006,214 patients with patho logically or cytologically proven stage Ⅳ NSCLC were included in this analysis.Of those patients,98 re ceived radiotherapy concurrently with 3-week cycle chemotherapy(group A),18 received radiotherapy con currently with weekly chemotherapy(group B) ,44 received chemotherapy alone,37 received radiotherapy a lone and 13 received sequential chemo-radiotherapy.The primary tumor was treated by three-dimensional conformal radiotherapy(3DCRT) or conventional radiotherapy with conventional fraefionation or late-course accelerated hyperfraction (LA H RT).Group A received 21-28 days cycle cisplatin-based chemotherapy (cis platin combined with PTX,DTY,NVB or Vp-16) ,and group B received weekly DDP combined with PTX or topteeon for 4-6 weeks.Results The follow-up rate was 99%.The 1-and 2-year overall survival rates of group A,group B,chemotherapy alone,radiotherapy alone and sequential chemo-radiotherapy were 41% and 11% ,16% and 0,31% and 7% ,34% and 10% ,26% and 3% ,respectively(x2 = 11.18,P=0.025).The patients with concurrent 3DCRT,LAHRT and radiotherapy dose≥70 Gy had better survival in group A than those in chemotherapy alone group.Patients who received≥2 cycles chemotherapy with concurrent radio therapy had longer survival time than those who had ≥2 cycles chemotherapy alone. Conclusions Con current chemotherapy and 3DCRT,LAHRT with the dose ≥70 Gy can improve the overall survival of patients with stage Ⅳ non-small cell lung cancer.
